Page last updated: 2024-12-06

aldrin-transdiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

aldrin-transdiol: dieldrin metabolite suggested as active neurotoxic form; RN refers to (1 alpha,2 alpha,3 beta,4 alpha,4a beta,5 alpha,8 alpha,8a beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121492700
MeSH IDM0049034

Synonyms (16)

Synonym
5,6,7,8,9,9-hexachloro-1,2,3,4,4a,5,8,8a-octahydro-1,4:5,8-dimethanonaphthalene-2,3-diol
trans-6,7-dihydroxydihydroaldrin
wl 40549
trans-aldrindiol
1,4:5,8-dimethanonaphthalene-2,3-diol, 5,6,7,8,9,9-hexachloro-1,2,3,4,4a,5,8,8a-octahydro-, stereoisomer
aldrin-transdiol
h9afn5yd9r ,
3106-29-4
unii-h9afn5yd9r
aldrindiol, trans-
wl-40549
1,4:5,8-dimethanonaphthalene-2,3-diol, 5,6,7,8,9,9-hexachloro-1,2,3,4,4a,5,8,8a-octahydro-, (1r,2s,3s,4s,4ar,5r,8s,8as)-rel-
(1s,2s,3r,4s,5s,6s,7r,8r)-1,8,9,10,11,11-hexachlorotetracyclo[6.2.1.13,6.02,7]dodec-9-ene-4,5-diol
Q27279794
DTXSID40953167
AKOS040750312

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The toxicology of dihydrodiol is more complex than what can be deduced solely on the basis of diminished bioavailability of the epoxide precursor, and the increased hydrophilicity associated with the dihydrodiol moiety."( Toxicological significance of dihydrodiol metabolites.
Hsia, MT, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]